PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Vertex Pharmaceuticals Incorporated (VRTX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US92532F1003

CUSIP

92532F100

Sector

Healthcare

IPO Date

Jul 24, 1991

Highlights

Market Cap

$126.19B

EPS (TTM)

-$1.91

PEG Ratio

1.32

Total Revenue (TTM)

$10.61B

Gross Profit (TTM)

$9.14B

EBITDA (TTM)

-$147.50M

Year Range

$341.90 - $519.88

Target Price

$515.77

Short %

1.66%

Short Ratio

4.16

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
VRTX vs. LLY VRTX vs. REGN VRTX vs. SHEL VRTX vs. BX VRTX vs. BMRN VRTX vs. VLO VRTX vs. ABBV VRTX vs. CRWD VRTX vs. MOH VRTX vs. XLE
Popular comparisons:
VRTX vs. LLY VRTX vs. REGN VRTX vs. SHEL VRTX vs. BX VRTX vs. BMRN VRTX vs. VLO VRTX vs. ABBV VRTX vs. CRWD VRTX vs. MOH VRTX vs. XLE

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Vertex Pharmaceuticals Incorporated, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


1,500.00%2,000.00%2,500.00%JuneJulyAugustSeptemberOctoberNovember
2,487.22%
1,450.45%
VRTX (Vertex Pharmaceuticals Incorporated)
Benchmark (^GSPC)

Returns By Period

Vertex Pharmaceuticals Incorporated had a return of 14.45% year-to-date (YTD) and 35.77% in the last 12 months. Over the past 10 years, Vertex Pharmaceuticals Incorporated had an annualized return of 15.45%, outperforming the S&P 500 benchmark which had an annualized return of 11.11%.


VRTX

YTD

14.45%

1M

-4.42%

6M

4.60%

1Y

35.77%

5Y (annualized)

17.32%

10Y (annualized)

15.45%

^GSPC (Benchmark)

YTD

23.08%

1M

0.10%

6M

10.70%

1Y

30.05%

5Y (annualized)

13.52%

10Y (annualized)

11.11%

Monthly Returns

The table below presents the monthly returns of VRTX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20246.51%-2.92%-0.65%-6.03%15.92%2.94%5.76%0.03%-6.21%2.34%14.45%
202311.88%-10.15%8.54%8.14%-5.04%8.76%0.12%-1.14%-0.17%4.13%-2.02%14.68%40.90%
202210.68%-5.36%13.46%4.69%-1.67%4.89%-0.49%0.48%2.76%7.76%1.41%-8.73%31.50%
2021-3.07%-7.22%1.10%1.54%-4.39%-3.36%-0.02%-0.64%-9.44%1.95%1.09%17.47%-7.08%
20203.70%-1.33%6.21%5.57%14.63%0.82%-6.31%2.62%-2.51%-23.43%9.31%3.77%7.94%
201915.21%-1.13%-2.54%-8.14%-1.66%10.35%-9.14%8.04%-5.89%15.38%13.44%-1.26%32.13%
201811.35%-0.50%-1.84%-6.03%0.55%10.36%2.99%5.34%4.52%-12.08%6.69%-8.34%10.58%
201716.56%5.53%20.67%8.18%4.48%4.26%17.81%5.74%-5.29%-3.82%-1.33%3.86%103.42%
2016-27.88%-5.80%-7.02%6.10%10.45%-7.65%12.76%-2.57%-7.72%-13.01%7.58%-9.73%-41.45%
2015-7.29%8.43%-1.22%4.50%4.06%-3.75%9.33%-5.54%-18.33%19.78%3.70%-2.73%5.92%
20146.38%2.30%-12.54%-4.27%6.74%31.03%-6.09%5.24%20.03%0.29%4.65%0.78%59.89%
20136.87%4.56%17.41%39.75%4.57%-0.34%-0.32%-5.83%0.89%-5.90%-2.70%7.03%77.33%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current risk-adjusted rank of VRTX is 82, placing it in the top 18% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of VRTX is 8282
Combined Rank
The Sharpe Ratio Rank of VRTX is 8181
Sharpe Ratio Rank
The Sortino Ratio Rank of VRTX is 8080
Sortino Ratio Rank
The Omega Ratio Rank of VRTX is 7777
Omega Ratio Rank
The Calmar Ratio Rank of VRTX is 9393
Calmar Ratio Rank
The Martin Ratio Rank of VRTX is 8080
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Vertex Pharmaceuticals Incorporated (VRTX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for VRTX, currently valued at 1.36, compared to the broader market-4.00-2.000.002.001.362.48
The chart of Sortino ratio for VRTX, currently valued at 2.20, compared to the broader market-4.00-2.000.002.004.002.203.33
The chart of Omega ratio for VRTX, currently valued at 1.28, compared to the broader market0.501.001.502.001.281.46
The chart of Calmar ratio for VRTX, currently valued at 2.79, compared to the broader market0.002.004.006.002.793.58
The chart of Martin ratio for VRTX, currently valued at 6.05, compared to the broader market0.0010.0020.0030.006.0515.96
VRTX
^GSPC

The current Vertex Pharmaceuticals Incorporated Sharpe ratio is 1.36. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Vertex Pharmaceuticals Incorporated with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.

Rolling 12-month Sharpe Ratio1.001.502.002.503.003.50JuneJulyAugustSeptemberOctoberNovember
1.36
2.48
VRTX (Vertex Pharmaceuticals Incorporated)
Benchmark (^GSPC)

Dividends

Dividend History


Vertex Pharmaceuticals Incorporated doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-12.00%-10.00%-8.00%-6.00%-4.00%-2.00%0.00%JuneJulyAugustSeptemberOctoberNovember
-9.88%
-2.18%
VRTX (Vertex Pharmaceuticals Incorporated)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Vertex Pharmaceuticals Incorporated. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Vertex Pharmaceuticals Incorporated was 91.77%, occurring on Nov 11, 2003. Recovery took 2677 trading sessions.

The current Vertex Pharmaceuticals Incorporated drawdown is 9.88%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-91.77%Nov 3, 2000757Nov 11, 20032677Jul 2, 20143434
-81.22%Jul 25, 1991228Jun 18, 1992993May 23, 19961221
-70.19%Feb 25, 1997383Aug 31, 1998363Feb 8, 2000746
-55.25%Mar 7, 200029Apr 14, 200043Jun 16, 200072
-49.1%Aug 20, 2015340Dec 22, 2016142Jul 19, 2017482

Volatility

Volatility Chart

The current Vertex Pharmaceuticals Incorporated volatility is 9.96%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%4.00%6.00%8.00%10.00%JuneJulyAugustSeptemberOctoberNovember
9.96%
4.06%
VRTX (Vertex Pharmaceuticals Incorporated)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Vertex Pharmaceuticals Incorporated over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Vertex Pharmaceuticals Incorporated.


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items